Neal Chaisson, MD
Critical Care Medicine · Cleveland, OHNPI 1932373826
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $340,874 of the $427,610 with a category attached, or 79.7%. Actelion Pharmaceuticals US, Inc. accounts for 68.6% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2023 at $224,959 and has fallen 60.3% since, to $89,279 in 2025. Among critical care medicine clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 177 payments — averaging $2415.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$293K
- United Therapeutics Corporation$73K
- Bayer$48K
- Merck$11K
- Gilead$2K
- Regeneron Healthcare Solutions, Inc.$40
- plus $12 from 1 others
Across 14 payments — averaging $1620.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$23K
What the payments were for
- Consulting fees$340,87480%
- Speaking & faculty fees$75,52318%
- Travel & lodging$7,8972%
- Food & beverage$3,1841%
- Education$1210%
- Gifts$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 22 | $293,395 |
| United Therapeutics Corporation | 96 | $73,058 |
| Bayer | 32 | $48,258 |
| Merck | 22 | $11,070 |
| Gilead | 3 | $1,777 |
| Regeneron Healthcare Solutions, Inc. | 1 | $40 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$427,610 in reported general payments places this provider in the 95th percentile of 285 critical care medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UptraviSelexipag | 64 | $1,352,357 |
| OpsumitMacitentan | 101 | $1,265,917 |
| Tyvaso DpiTreprostinil | 48 | $1,127,983 |
| AdempasRiociguat | 59 | $805,516 |
| WinrevairSotatercept-Csrk | 28 | $433,958 |
| Ambrisentan | 133 | $385,542 |
| LetairisAmbrisentan | 30 | $372,800 |
| Orenitram ErTreprostinil Diolamine | 50 | $350,028 |
| AdcircaTadalafil | 45 | $158,472 |
| Sildenafil Citrate | 109 | $60,704 |
| Tadalafil | 66 | $48,988 |
| Azithromycin | 29 | $698 |
| Spironolactone | 17 | $128 |
| Furosemide | 29 | $109 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $293,395 | $2,618,273165 claims |
| BayerAdempas | $48,258 | $805,51659 claims |
| MerckWinrevair | $11,070 | $433,95828 claims |
| GileadLetairis | $1,777 | $372,80030 claims |
| United Therapeutics CorporationAdcirca | $73,058 | $158,47245 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 285 critical care medicine providers in Ohio.
Other critical care medicine in Cleveland
- Robert SchilzCleveland$356K
- Chiedozie UdehCleveland$24K
- Kingman StrohlCleveland$10K
- Arvind SugunessCleveland$5K
- Maeve MacmurdoCleveland$4K
- Eric HarvesterCleveland$4K
- Angela JohnsonCleveland$3K
- Zahra ZiaCleveland$2K
- Rafid FadulCleveland$2K
- Sany KumarCleveland$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.